Disease · MONDO_0000548
Targets28
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 28
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PARP1 | Poly [ADP-ribose] polymerase 1 | 3 | Poly [ADP-ribose] polymerase-1 inhibitor | Phase 2 | https://conductscience.org/library/genes/142 | Drugs and targets |
| PARP2 | Poly [ADP-ribose] polymerase 2 | 3 | Poly [ADP-ribose] polymerase 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/10038 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor 2 | 2 | Vascular endothelial growth factor receptor 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 1 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor 3 | 1 | Vascular endothelial growth factor receptor 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 1 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| MET | Hepatocyte growth factor receptor | 1 | Hepatocyte growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4233 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 1 | Platelet-derived growth factor receptor beta inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | 1 | T-cell immunoreceptor with Ig and ITIM domains inhibitor | Phase 2 | https://conductscience.org/library/genes/201633 | Drugs and targets |
| TUBA1A | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7277 | Drugs and targets |
| TUBB | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 1 | Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/81027 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000548/targets